The user has been on finasteride for 7 months, seeing darker, fuller hair but experiencing significant shedding. They are considering adding minoxidil to their treatment to address the shedding.
Finasteride prescriptions in France now require an annual certificate acknowledging psychiatric and sexual risks, as the European Medicines Agency recognizes these risks. The conversation discusses the potential mental health effects of Finasteride, with some users reporting side effects and others questioning the statistical significance of these findings.
The user tried topical minoxidil, topical and oral finasteride, and switched to dutasteride and oral minoxidil without success in stopping hair loss. Suggestions included continuing treatment longer, trying microneedling, and considering a hair transplant.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
The conversation is about hair loss treatments, specifically the lack of improvement after one year of using oral finasteride and topical minoxidil. Suggestions include switching to stronger medications like dutasteride and oral minoxidil, considering a hair transplant, and possibly using microneedling or tretinoin.
A new light therapy claims to reduce hair loss markers by 92% using a specific wavelength range. Users discuss the cost and effectiveness of devices, with some expressing skepticism and others considering alternative treatments like red light therapy and vitamin D exposure.
A 24-year-old scaled his company to over $100k MRR but experienced hair loss, attributing it to stress and genetics despite using treatments like Dutasteride and Minoxidil. Many suggest embracing baldness, focusing on health, or considering additional treatments like Finasteride, while others debate the impact of stress versus genetics on hair loss.
Most users did not visit a dermatologist before starting finasteride, opting to purchase it directly or through a primary care physician. Some users shared experiences of side effects and emphasized the potential benefits of medical advice and monitoring.
People are using finasteride, minoxidil, and dutasteride for hair thinning, with some recommending oral forms. Other products like IntelliGent shampoo, CeraVe 1% zinc shampoo, and conditioners are mentioned, but they are seen as supplemental to DHT blockers.
The user experienced persistent acne and skin issues with dutasteride, leading them to stop its use. They switched to finasteride, which caused mild acne and potential liver concerns, prompting consideration of alternative treatments like topical finasteride and GHK-Cu.
A 23-year-old is experiencing hair that is thick at the ends but thin at the roots despite using minoxidil and finasteride for 10 months. They are concerned about whether this is normal or a sign of miniaturization and seek advice on reversing or improving the condition.
The user has been using minoxidil for 9 months and finasteride for 3 months to address hair thinning, noticing some new miniature hairs but uncertain about significant regrowth. Opinions vary, with some suggesting the hair looks darker and stabilized, while others recommend additional treatments like oral minoxidil, microneedling, or tretinoin.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
The conversation discusses reducing hair fall by addressing dandruff with anti-dandruff shampoo, regular oiling, and stress management through meditation and yoga. Other users mention using ketoconazole, vitamin D, and finasteride, with some experiencing side effects.
A doctor recommended Follivera as a minoxidil alternative, but users are skeptical, suggesting minoxidil, finasteride, or dutasteride for hair loss. Some users mention adenosine and piroctone olamine as potentially helpful ingredients.
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
A user discusses using tazarotene to enhance minoxidil's effectiveness for hair regrowth, believing it will make a significant difference. Others caution about potential risks of retinoids accelerating hair loss in some individuals.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
The user shared their one-year progress using finasteride, occasionally using topical minoxidil, and reported significant hair improvement, especially on the crown. They experienced no side effects and noted that finasteride addresses the underlying hormonal issue, while minoxidil promotes hair growth.
Celebrities often use hairpieces, transplants, or medications like Minoxidil to maintain their hairlines. Hair transplants require ongoing medication, and opinions on their success vary.
Estrogen injections significantly improved hair growth, particularly on the crown, after stopping finasteride. Monotherapy with estrogen led to hairline improvement, but also caused sterility and potential feminization effects.
A 33-year-old attempted hair regrowth after 10 years of baldness using topical finasteride, minoxidil, micro-needling, a laser cap, and later oral dutasteride. They noticed some regrowth, especially vellus hairs, and are considering a hair transplant or other treatments despite side effects.
The user has been using minoxidil and finasteride for nearly two years, seeing some prevention of further hair loss and possible regrowth. Many suggest trying dutasteride or considering a hair transplant as the next step.
A 31-year-old male experienced significant hair regrowth after 6 months using daily 0.5 mg dutasteride, 5% topical minoxidil twice a day, occasional dermarolling, and hair supplements. He reported a slight decrease in libido initially but no other side effects, and there's potential for further improvement up to 12–18 months.
A 24-year-old male with crown thinning and an oily scalp is seeking advice on shampoo recommendations and whether to restart minoxidil or try a hair growth serum. He is concerned about daily shampooing and managing greasy hair.
The user is using oral minoxidil, finasteride, and a dermaroller for hair loss but is not seeing significant progress after three months. Suggestions include continuing treatment for at least a year, considering dutasteride, adding topical minoxidil, or possibly getting a hair transplant.
The conversation discusses the use of microneedling as a complementary treatment for hair loss alongside oral minoxidil and dutasteride. Opinions vary on its effectiveness, with some users supporting its benefits for hair growth and others questioning its efficacy without topical minoxidil.
Scientists have successfully grown functional hair follicles in the lab, marking a significant advancement in hair regeneration research. A user shared their personal experience with hair loss treatments, including Minoxidil and Finasteride, and plans to share a detailed protocol for hair restoration.
A user has been on finasteride for 8 months with worsening hair thinning and is considering dutasteride. Others suggest adding minoxidil, maintaining a healthy lifestyle, and possibly trying RU58841.
A 23-year-old woman is considering starting minoxidil for hair thinning but is concerned about its long-term use and effectiveness. Recommendations include consulting a doctor, checking ferritin levels, and considering treatments like spironolactone or finasteride, while minoxidil is suggested for regrowth but not as a primary treatment.